234 related articles for article (PubMed ID: 31622114)
1. Nivolumab for the treatment of small cell lung cancer.
Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
[No Abstract] [Full Text] [Related]
2. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
3. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
[TBL] [Abstract][Full Text] [Related]
4. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Cope S; Keeping ST; Goldgrub R; Ayers D; Jansen JP; Penrod JR; Korytowsky B; Juarez-Garcia A; Yuan Y
J Comp Eff Res; 2019 Jul; 8(10):733-751. PubMed ID: 31237143
[No Abstract] [Full Text] [Related]
6. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
Armstrong SA; Liu SV
Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Malhotra J; Nikolinakos P; Leal T; Lehman J; Morgensztern D; Patel JD; Wrangle JM; Curigliano G; Greillier L; Johnson ML; Ready N; Robinet G; Lally S; Maag D; Valenzuela R; Blot V; Besse B
J Thorac Oncol; 2021 Sep; 16(9):1559-1569. PubMed ID: 33652156
[TBL] [Abstract][Full Text] [Related]
10. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
11. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
[TBL] [Abstract][Full Text] [Related]
12. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
13. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
15. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
16. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ipilimumab in non-small-cell lung cancer.
Reck M; Borghaei H; O'Byrne KJ
Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
[TBL] [Abstract][Full Text] [Related]
18. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.
Rijavec E; Indini A; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Grossi F
Expert Rev Anticancer Ther; 2021 Jul; 21(7):705-713. PubMed ID: 33719827
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
